サマリー

Point Of Care Diagnostics 市場の成長とトレンド

グランドビューリサーチ社の最新レポートによると、世界のPoint of Care Diagnosticsの市場規模は2030年には685億9000万米ドルに達すると予測されています。2022年から2030年にかけては、CAGR6.8%で拡大すると予測されています。Telehealth enabled POCTなどの先進技術の導入が、市場成長を促進すると予想されます。さらに、老年人口の増加や、利用しやすい在宅ケアのニーズが、市場を牽引すると予測されています。

アフリカや中南米などの新興国におけるPOCTの採用は、世界のPOCT市場の成長決定要因になると予想されます。当局は医療システムの分散化を進め、投資を増やしています。例えば、ケニアのアフリカ規制では、新しい機器の調達による施設の近代化に向けて、政府が主導するManaged Equipment Servicesプロジェクトに346.7米ドルが割り当てられました。保健省はGEヘルスとフィリップスを選び、47カ国で機器を提供することにしました。同様に、中南米では体外用診断薬の検査が分散化され、特に感染症分野での安価なPOCTに対する地域の既存の需要を満たすために、民間プレイヤーが戦略的イニシアチブをとることが奨励されています。

現在開発されているPOC機器や検査は、がん、妊娠、感染症など、さまざまな医療診断用途で採用されています。患者や医師は、POC検査を利用して病状のスクリーニング、診断の確認、患者の健康状態に応じた適切な治療方法の設計を行っています。しかし、医師、患者、介護者などの消費者により、POC検査に対する熱意は大きく異なっています。このようなPOC診断製品のダイナミックな消費パターンは、経済的な拡張性、金銭的な利益、国民皆保険制度の欠如にも起因しています。

COVID-19では、世界中でロックダウンが実施されたため、バーチャル訪問や迅速な診断テストが必要となり、患者が病院を訪れるのを避けることができるようになりました。ロックダウン後、eHealth戦略は、自動患者予約システム、検査結果送信システム、医療従事者のコミュニケーションシステム、企業や政府による医療品調達システムなど、新たな優先分野と投資対象になっています。パンデミック後も、特に持病のある患者には、在宅医療を優先的に提供することが予想されます。例えば、ニューロメトリクス社は、末梢神経障害のPOCTであるDPNCheckの事業展開のためのチームを任命しました。このチームは、ヘルスケア市場での足跡を拡大し、メディケア・アドバンテージの人々に焦点を当てる役割を担っています。

Point Of Care Diagnostics 市場レポートハイライト

- グルコース検査製品セグメントは、2021年に2番目に大きな収益シェアを占めた。糖尿病の高い有病率と、血糖値の常時モニタリングの必要性が、このセグメントの成長に寄与している

- 家庭用製品セグメントは、COVID-19の家庭用または自己検査の大きな普及に起因して、予測期間中に大きく成長すると予想される。POCTデバイスは使いやすく、患者のサンプルに含まれるより単純な標的分析物を検査するための最新のラボインフラを義務付ける必要はない。

- 2021年の世界市場は、新技術に対する需要の高まり、主要プレイヤーの層の厚さ、医療インフラの充実により、北米が圧倒的なシェアを占めています。

- アジア太平洋地域は、がん、糖尿病、心血管疾患、感染症などの有病率の上昇により、将来的に大きく成長すると予想されています。可処分所得が限られている人口の増加が、同地域の主要プレイヤーにとって潜在的なターゲット市場となっています。

ページTOPに戻る

目次

Table of Contents

Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Market Categorization
1.4.2 Point-Of-Care Testing
1.4.2.1 Poc-End-Use Penetration Mapping
1.4.3 Pricing Analysis
1.4.4 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom Up Approach
1.7 Global Market: Cagr Calculation
1.8 List Of Secondary Sources
1.9 List Of Primary Sources
1.10 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Market Summary
Chapter 3 Market Variables, Trends, And Scope
3.1 Market Trends And Outlook
3.2 Market Segmentation And Scope
3.3 Parent Market Outlook
3.3.1 Related/Ancillary Market Outlook
3.3.1.1 Molecular Technology Intervention
3.3.1.1.1 Key Factors Considered For Analyzing Molecular Technology Interventions Across Poc Testing
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Introduction Of Clia Waived Tests
3.4.1.2 Rise In Funding From Government And Private Institutions
3.4.1.3 Growing Geriatric Population Base
3.4.1.4 Growing Prevalence Of Target Diseases
3.4.1.5 Growing Demand For Home Healthcare And The Introduction Of Advance Technology Enabled Products
3.4.2 Market Restraint Analysis
3.4.2.1 High Procedure Costs Coupled With Limited Adoption Of Poc Devices In Certain Emerging Regions
3.4.2.2 Presence Of Ambiguous Regulatory As Well As Reimbursement Framework For Primary Care Setting
3.4.3 Market Challenge Analysis
3.4.3.1 Poc Devices Pose Challenges In Maintaining The Quality Standards
3.4.4 Market Opportunity Analysis
3.4.4.1 Networking & Remote Access Integration Of Poc Diagnostics Products
3.4.4.1.1 Smartphone Orientation
3.4.4.1.2 Embedded Vision-Based Solutions
3.4.4.1.3 Digital Technologies
3.5 Penetration And Growth Prospect Mapping For Point Of Care Products, 2021
3.6 Swot By Pest Analysis
3.6.1 Political Landscape
3.6.2 Economic Landscape
3.6.3 Social Landscape
3.6.4 Technology Landscape
3.7 Industry Analysis – Porter’s
3.7.1 Bargaining Power Of Suppliers: Moderate
3.7.2 Bargaining Power Of Buyers: Moderate
3.7.3 Threat Of Substitution: Low
3.7.4 Threat Of New Entrants: Low
3.7.5 Competitive Rivalry: High
3.8 Major Deals & Strategic Alliances Analysis
3.8.1 Joint Ventures
3.8.2 Mergers & Acquisitions
3.8.3 Licensing & Partnership
3.9 Market Entry Strategies
3.10 Price-Cost-Margin Analysis For Point-Of-Care Testing
3.11 User Perspective Analysis
3.11.1 Consumer Behavior Analysis
3.12 Technology Overview
3.13 Poc Diagnostics: Market Influencers
3.13.1 High Sensitivity
3.13.2 Shift To Molecular Diagnostics
3.14 Product Positioning Analysis, 2021
3.14.1 Glucose Testing
3.14.2 Hb1ac Testing
3.14.3 Coagulation Testing
3.14.4 Fertility/Pregnancy
3.14.5 Infectious Disease
3.14.6 Cardiac Markers
3.14.7 Thyroid Stimulating Hormone
3.14.8 Haematology
3.14.9 Primary Care Systems
3.14.10 Decentralized Clinical Chemistry
3.14.11 Feces
3.14.12 Lipid Testing
3.14.13 Cancer Marker
3.14.14 Blood Gas/Electrolytes
3.14.15 Ambulatory Chemistry
3.14.16 Drug Of Abuse (Doa) Testing
3.14.17 Urinalysis/Nephrology
3.15 Regulatory Framework Analysis For U.S. Point Of Care Diagnostics
3.16 Regulatory Framework Analysis For Europe Point Of Care Diagnostics
3.17 Regulatory Framework Analysis For Japan Point Of Care Diagnostics
Chapter 4 Covid-19 Impact Analysis
4.1 Overview
4.1.1 Covid-19 Point-Of-Care Diagnostics: Technology Overview
4.1.2 Covid-19 Point-Of-Care Diagnostics: Regulatory Overview
Chapter 5 Competitive Analysis.
5.1 Recent Developments & Impact Analysis, By Key Market Participants
5.2 Company/Competition Categorization
5.3 Vendor Landscape
5.3.1 Key Distributors Marketing Channels
5.3.1.1 Abbott Diagnostics
5.3.1.1.1 Abbott Diagnostics: Marketing Channels & Distribution Network For Poc
5.3.1.1.2 Alere Inc.
5.3.1.1.2.1 Alere: Marketing Channels & Distribution Network For Poc
5.3.1.2 Roche Diagnostics
5.3.1.2.1 Roche Diagnostics: Marketing Channels & Distribution Network For Poc
5.3.1.3 Siemens Healthcare
5.3.1.3.1 Siemens Healthcare: Marketing Channels & Distribution Network For Poc
5.3.1.4 Danaher Corporation
5.3.1.4.1 Danaher Corporation: Marketing Channels & Distribution Network For Poc
5.3.1.5 Instrumentation Laboratory Spa.
5.3.1.5.1 Instrumentation Laboratory Spa.: Marketing Channels & Distribution Network For Poc
5.3.1.6 Becton Dickinson
5.3.1.6.1 Becton Dickinson.: Marketing Channels & Distribution Network For Poc
5.3.2 Key Customers
5.4 Key Company Market Ranking, 2021
5.4.1 Company Size
5.4.2 Distribution Network
5.4.3 Product Portfolio
5.4.4 Segment Coverage
5.4.5 Geographic Presence
5.4.6 Collaborations
5.4.7 Conclusion
5.5 Public Companies
5.5.1 Number Of Products
5.5.2 Market Penetration
5.5.3 Strategic Initiatives
5.5.4 Segment Coverage
5.5.5 Geographical Presence
5.5.6 Competitive Dashboard Analysis
5.6 Market Differentiators
5.6.1 Application Trends
5.6.2 Technology Trends
5.6.3 Test Location Trends
5.6.4 End-Use Trends
5.6.5 Regional Trends
5.7 Private Companies
5.7.1 New Entrants/Emerging Players
5.8 Regional Mapping: Public And Private Companies
Chapter 6 Product Business Analysis
6.1 Point-Of-Care (Poc) Diagnostics Market: Product Movement Analysis
6.1.1 Glucose Testing
6.1.1.1 Glucose Testingpoint-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.2 Hb1ac Testing
6.1.2.1 Hb1ac Testing Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.3 Coagulation Testing
6.1.3.1 Coagulation Testing Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.4 Fertility/Pregnancy
6.1.4.1 Fertility/Pregnancy Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5 Infectious Diseases
6.1.5.1 Infectious Disease Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.2 Hiv Poc
6.1.5.2.1 Hiv Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.3 Clostridium Difficile Poc
6.1.5.3.1 Clostridium Difficile Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.4 Hbv Poc
6.1.5.4.1 Hbv Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.5 Pneumonia Or Streptococcus Associated Infections
6.1.5.5.1 Pneumonia Or Streptococcus Associated Infections Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.6 Respiratory Syncytial Virus (Rsv) Poc
6.1.5.6.1 Respiratory Syncytial Virus (Rsv) Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.7 Hpv Poc
6.1.5.7.1 Hpv Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.8 Influenza/Flu Poc
6.1.5.8.1 Influenza/Flu Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.9 Hcv Poc
6.1.5.9.1 Hcv Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.10 Mrsa Poc
6.1.5.10.1 Mrsa Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.11 Tb And Drug-Resistant Tb Poc
6.1.5.11.1 Tb And Drug-Resistant Tb Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.12 Hsv Poc
6.1.5.12.1 Hsv Poc Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.5.13 Covid-19
6.1.5.13.1 Covid-19 Diagnostics Market Estimates And Forecast, 2020 – 2030 (Usd Million)
6.1.5.14 Other Infectious Diseases
6.1.5.14.1 Other Infectious Disease Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.6 Cardiac Markers
6.1.6.1 Cardiac Markers Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.7 Thyroid Stimulating Hormone
6.1.7.1 Thyroid Stimulating Hormone Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.8 Hematology
6.1.8.1 Hematology Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.9 Primary Care Systems
6.1.9.1 Primary Care Systems Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.10 Decentralized Clinical Chemistry
6.1.10.1 Decentralized Clinical Chemistry Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.11 Feces
6.1.11.1 Feces Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.12 Lipid Testing
6.1.12.1 Lipid Testing Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.13 Cancer Marker
6.1.13.1 Cancer Marker Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.14 Blood Gas/Electrolytes
6.1.14.1 Blood Gas/Electrolytes Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.15 Ambulatory Chemistry
6.1.15.1 Ambulatory Chemistry Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.16 Drug Of Abuse (Doa) Testing
6.1.16.1 Drug Of Abuse (Doa) Testing Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
6.1.17 Urinalysis/Nephrology
6.1.17.1 Urinalysis/Nephrology Point-Of-Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (Usd Million)
Chapter 7 End-Use Business Analysis
7.1 Point-Of-Care (Poc) Diagnostics Market: End-Use Movement Analysis
7.1.1 Clinics
7.1.1.1 Point-Of-Care (Poc) Diagnostics Market For Clinics, 2018 - 2030 (Usd Million)
7.1.1.2 Pharmacy & Retail Clinics
7.1.1.2.1 Point-Of-Care (Poc) Diagnostics Market For Pharmacy & Retail Clinics, 2018 - 2030 (Usd Million)
7.1.1.3 Physician Office
7.1.1.3.1 Point-Of-Care (Poc) Diagnostics Market For Physician Office, 2018 - 2030 (Usd Million)
7.1.1.4 Urgent Care Clinics
7.1.1.4.1 Point-Of-Care (Poc) Diagnostics Market For Urgent Care Clinics, 2018 - 2030 (Usd Million)
7.1.1.5 Non-Practice Clinics
7.1.1.5.1 Point-Of-Care (Poc) Diagnostics Market For Non-Practice Clinics, 2018 - 2030 (Usd Million)
7.1.2 Hospitals
7.1.2.1 Point-Of-Care (Poc) Diagnostics Market For Hospitals, 2018 - 2030 (Usd Million)
7.1.3 Home
7.1.3.1 Point-Of-Care (Poc) Diagnostics Market For Home, 2018 - 2030 (Usd Million)
7.1.4 Assisted Living Healthcare Facilities
7.1.4.1 Point-Of-Care (Poc) Diagnostics Market For Assisted Living Healthcare Facilities, 2018 - 2030 (Usd Million)
7.1.5 Laboratory
7.1.5.1 Point-Of-Care (Poc) Diagnostics Market For Laboratory, 2018 - 2030 (Usd Million)
Chapter 8 Region Business Analysis
8.1 Point-Of-Care (Poc) Diagnostics Market: Regional Movement Analysis, 2021 & 2030
8.2 North America
8.2.1.1 North America Point-Of-Care (Poc) Diagnostics Market, 2018 - 2030 (Usd Million)
8.2.2 U.S.
8.2.3 Canada
8.3 Europe
8.3.1.1 Europe Point-Of-Care (Poc) Diagnostics Market, 2018 - 2030 (Usd Million)
8.3.2 Germany
8.3.3 U.K.
8.3.4 France
8.3.5 Italy
8.3.6 Spain
8.3.7 Russia
8.4 Asia Pacific
8.4.1.1 Asia Pacific Point-Of-Care (Poc) Diagnostics Market, 2018 - 2030 (Usd Million)
8.4.2 Japan
8.4.3 China
8.4.4 India
8.4.5 Australia
8.4.6 South Korea
8.5 Latin America
8.5.1.1 Latin America Point-Of-Care (Poc) Diagnostics Market, 2018 - 2030 (Usd Million)
8.5.2 Brazil
8.5.3 Mexico
8.6 Middle East & Africa (Mea)
8.6.1.1 Middle East & Africa Point-Of-Care (Poc) Diagnostics Market, 2018 - 2030 (Usd Million)
8.6.2 South Africa
8.6.3 Saudi Arabia
Chapter 9 Company Profile
9.1 Company Profiles
9.1.1 Wipro Limited
9.1.1.1 Company Overview
9.1.1.2 Financial Performance
9.1.1.3 Product Benchmarking
9.1.2 Zoe Global Limited
9.1.2.1 Company Overview
9.1.2.2 Product Benchmarking
9.1.3 Vocalis Health
9.1.3.1 Company Overview
9.1.3.2 Product Benchmarking
9.1.3.3 Strategic Initiatives
9.1.4 Darwinai
9.1.4.1 Company Overview
9.1.4.2 Product Benchmarking
9.1.4.3 Strategic Initiatives
9.1.5 Biocogniv, Inc.
9.1.5.1 Company Overview
9.1.5.2 Product Benchmarking
9.1.5.3 Strategic Initiatives
9.1.6 Laipac Technology, Inc.
9.1.6.1 Company Overview
9.1.6.2 Product Benchmarking
9.1.6.3 Strategic Initiatives
9.1.7 Gauss Surgical
9.1.7.1 Company Overview
9.1.7.2 Product Benchmarking
9.1.7.3 Strategic Initiatives
9.1.8 Oxford Immune Algorithmics Ltd.
9.1.8.1 Company Overview
9.1.8.2 Product Benchmarking
9.1.8.3 Strategic Initiatives
9.1.9 F. Hoffmann-La Roche Ltd.
9.1.9.1 Company Overview
9.1.9.2 Financial Performance
9.1.9.3 Product Benchmarking
9.1.9.4 Strategic Initiatives
9.1.10 Qiagen
9.1.10.1 Company Overview
9.1.10.2 Financial Performance
9.1.10.3 Product Benchmarking
9.1.10.4 Strategic Initiatives
9.1.11 Danaher Corporation
9.1.11.1 Company Overview
9.1.11.2 Beckman Coulter, Inc.
9.1.11.2.1 Company Overview
9.1.11.2.2 Radiometer Medical Aps
9.1.11.2.3 Hemocue Ab
9.1.11.3 Financial Performance
9.1.11.4 Product Benchmarking
9.1.11.5 Strategic Initiatives
9.1.12 Becton Dickinson (Bd)
9.1.12.1 Company Overview
9.1.12.2 Financial Performance
9.1.12.3 Product Benchmarking
9.1.12.4 Strategic Initiatives
9.1.13 Biomerieux Sa
9.1.13.1 Company Overview
9.1.13.2 Financial Performance
9.1.13.3 Product Benchmarking
9.1.13.4 Strategic Initiatives
9.1.14 Abbott
9.1.14.1 Company Overview
9.1.14.2 Alere, Inc.
9.1.14.2.1 Company Overview
9.1.14.3 Financial Performance
9.1.14.4 Product Benchmarking
9.1.14.5 Strategic Initiatives
9.1.14.5.1 Strategic Initiatives (Alere)
9.1.15 Siemens Healthcare Ag
9.1.15.1 Company Overview
9.1.15.2 Financial Performance
9.1.15.3 Product Benchmarking
9.1.15.4 Strategic Initiatives
9.1.16 Zoetis, Inc.
9.1.16.1 Company Overview
9.1.16.2 Abaxis
9.1.16.3 Company Overview
9.1.16.4 Financial Performance
9.1.16.4.1 Financial Performance (Abaxis)
9.1.16.5 Product Benchmarking
9.1.16.6 Strategic Initiatives
9.1.17 Instrumentation Laboratory
9.1.17.1 Company Overview
9.1.17.2 Accriva Diagnostics
9.1.17.2.1 Company Overview
9.1.17.3 International Technidyne Corporation (Itc)
9.1.17.3.1 Company Overview
9.1.17.4 Financial Performance (Instrumentation Laboratory)
9.1.17.4.1 Financial Performance (International Technidyne)
9.1.17.5 Product Benchmarking
9.1.17.6 Strategic Initiatives
9.1.18 Nova Biomedical
9.1.18.1 Company Overview
9.1.18.2 Financial Performance
9.1.18.3 Product Benchmarking
9.1.18.4 Strategic Initiatives
9.1.19 Trividia Health, Inc.
9.1.19.1 Company Overview
9.1.19.2 Financial Performance
9.1.19.3 Product Benchmarking
9.1.19.4 Strategic Initiatives
9.1.20 Quidel Corporation
9.1.20.1 Company Overview
9.1.20.2 Financial Performance
9.1.20.3 Product Benchmarking
9.1.20.4 Strategic Initiatives
9.1.21 Trinity Biotech
9.1.21.1 Company Overview
9.1.21.2 Financial Performance
9.1.21.3 Product Benchmarking
9.1.21.4 Strategic Initiatives
9.1.22 Sekisui Diagnostics
9.1.22.1 Company Overview
9.1.22.2 Product Benchmarking
9.1.22.3 Strategic Initiatives
9.1.23 Orasure Technologies, Inc.
9.1.23.1 Company Overview
9.1.23.2 Financial Performance
9.1.23.3 Product Benchmarking
9.1.23.4 Strategic Initiatives
9.1.24 Nipro
9.1.24.1 Company Overview
9.1.24.2 Financial Performance
9.1.24.3 Product Benchmarking
9.1.25 Spectral Medical Inc.
9.1.25.1 Company Overview
9.1.25.2 Financial Performance
9.1.25.3 Product Benchmarking